Abstract
Gliomatosis peritonei (GP) is a rare condition characterized by the presence of mature glial tissue within the peritoneum. It is infrequently observed in young women or pediatric patients with ovarian teratomas. This report describes a case of ovarian immature teratoma (OIT) associated with both GP and nodal gliomatosis (NG)—the metastasis of mature neuroglial components to the lymph nodes.
Introduction
Ovarian immature teratomas (OIT) are malignant germ cell tumors containing tissues derived from all three germ layers, notably including immature neuroepithelium. A rare but significant association exists between OIT and Gliomatosis Peritonei (GP), where thousands of benign, mature glial nodules scatter across the peritoneal surface. Even rarer is Nodal Gliomatosis (NG), involving the spread of this mature tissue to regional lymph nodes. With only approximately 100 cases of GP reported worldwide, standardized management protocols remain elusive due to the condition's extreme rarity.
Clinical Presentation and Diagnostics
A 23-year-old patient presented with a significant 20 cm pelvic mass. Clinical evaluation included physical examination, serum tumor marker analysis (CA125, CA19-9, HE4), and advanced imaging. Enhanced CT scans were pivotal in identifying the extent of the disease, revealing a large, heterogeneous mass occupying the pelvic and abdominal cavities, accompanied by numerous peritoneal nodules.
Surgical and Pathological Findings
The patient underwent a transabdominal right adnexectomy combined with pelvic and para-aortic lymph node dissection. Histopathological analysis of the primary tumor confirmed a Grade G1 (low-grade) immature teratoma.
To differentiate the peritoneal nodules and lymph node involvement from malignant spread, the authors utilized Immunohistochemistry (IHC). The tissues tested positive for Glial Fibrillary Acidic Protein (GFAP), confirming they consisted of mature, benign glial tissue. This finding established the diagnosis of concurrent GP and NG, highlighting that even mature tissue can metastasize via lymphatic vessels.
Discussion: The "Benign" Metastasis Paradox
The most striking feature of GP and NG is the "Benign Metastasis Paradox": while the primary OIT is malignant, the secondary implants are histologically mature and benign. This can lead to a clinical "reversal" where the patient's condition shifts from malignant to benign as the tissue matures.
Pathogenesis and Diagnostic Challenges
Two primary theories explain the development of these glial nodules:
- Spillage: Malignant cells leak from a ruptured tumor and subsequently mature within the abdominal cavity.
- Metaplasia: Multipotential stem cells in the peritoneum differentiate into glial cells in response to chemical signals from the tumor.
Clinically, GP often mimics tuberculous peritonitis or peritoneal carcinomatosis during surgery. Intraoperative frozen section pathology is essential to prevent aggressive over-treatment.
Conclusion and Prognosis
While GP generally suggests a more favorable prognosis, the combination with OIT requires intensive long-term follow-up. In this case, a 4x2 cm hepatic recurrence (also Grade G1 OIT) was detected six months post-surgery, requiring further laparoscopic resection.
Currently, there is no "gold standard" for whether these patients require aggressive chemotherapy if the implants are purely mature. Future molecular genetic studies are needed to definitively determine the origin of these nodules, which will help refine clinical surveillance and treatment strategies for this rare triad.
Summary updated